证券代码：000615 证券简称：*ST美谷 公告编号：2026-023 九州美谷科技股份有限公司 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要提示： 1、变更后的公司名称（中文）：九州美谷科技股份有限公司 2、变更后的公司名称（英文）：Jointown Aesthetics Valley Co.,Ltd. 3、证券简称暂未变更，证券代码仍为"000615" 一、变更公司全称及相关事项的说明 九州美谷科技股份有限公司（曾用名：奥园美谷科技股份有限公司，以下简 称"公司"）分别于 2026 年 1 月 7 日、2026 年 1 月 26 日召开第十一届董事会 第三十一次会议、2026 年第一次临时股东会，审议通过了《关于修订<公司章程> 及部分公司制度的议案》，同意公司变更中文名称和英文名称、增加注册资本等， 并以市场监督管理部门最终审批意见为准，具体详见公司于 2026 年 1 月 9 日在 巨潮资讯网（www.cninfo.com.cn，下同）披露的《关于修订<公司章程>和部分 公司制度的公告》《第十一届董事会第三十一次会 ...

证券代码：000615 证券简称：*ST美谷 公告编号：2026-022 奥园美谷科技股份有限公司 关于新增诉讼事项的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次案件所处的诉讼阶段：一审尚未开庭审理； 2、上市公司所处的当事人地位：被追加为被告； 3、涉案金额：约 4,427.78 万元； 4、对上市公司损益产生的影响：本次诉讼尚未开庭审理，后续判决结果尚 存在不确定性，对公司本期期末业绩的影响存在不确定性，最终以法院判决或执 行结果以及会计师事务所年度审计结果为准。 一、本次诉讼的基本情况 奥园美谷科技股份有限公司（以下简称"公司""奥园美谷"）于近日收到 襄阳市襄城区人民法院送达的传票和应诉通知书，具体诉讼情况如下： 被告二：田汉 3、原告诉讼请求： （1）判令被告京汉控股回购原告持有的湖北金环绿色纤维有限公司（以下 简称"金环绿色纤维"）4.5946%股权，并配合办理股权变更登记手续； （2）判令被告京汉控股向原告支付股权回购款，包含投资本金 34,000,000 1 1、案由 合同纠纷 受理法院：襄阳市襄城区人民法院，案号 ...

Core Viewpoint - The medical beauty sector experienced a rise of 2.68% on February 2, with Huaxi Biological leading the gains, while the overall market indices, Shanghai Composite and Shenzhen Component, saw declines of 2.48% and 2.69% respectively [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4015.75, down 2.48% [1] - The Shenzhen Component Index closed at 13824.35, down 2.69% [1] - The medical beauty sector stocks showed varied performance, with Huaxi Biological rising by 5.24% to a closing price of 47.18 [1] Group 2: Stock Details - Huaxi Biological (688363) had a trading volume of 118,200 shares and a transaction value of 562 million yuan [1] - Aimei Ke (300896) closed at 141.14, up 1.01%, with a trading volume of 47,500 shares and a transaction value of 683 million yuan [1] - ST Meigu (000615) closed at 3.08, up 0.33%, with a trading volume of 115,100 shares [1] - Jinbo Biological (920982) closed at 214.89, down 2.94%, with a trading volume of 9,949 shares and a transaction value of 217 million yuan [1] Group 3: Fund Flow Analysis - The medical beauty sector saw a net inflow of 100 million yuan from main funds, while retail investors experienced a net outflow of 59.89 million yuan [1] - Aimei Ke had a main fund net inflow of 55.54 million yuan, but a net outflow of 33.36 million yuan from retail investors [2] - Huaxi Biological experienced a main fund net inflow of 44.73 million yuan, with retail investors showing a net outflow of 27.92 million yuan [2]

Core Insights - The report provides an analysis of the hair medical industry in China, highlighting key players, market share, and competitive dynamics. Group 1: Industry Overview - The main listed companies in the hair medical industry include Yonghe Medical, Xianju Pharmaceutical, ST Meigu, Yisheng Pharmaceutical, Zhendong Pharmaceutical, International Medical, Kanghui Pharmaceutical, Kangyuan Pharmaceutical, Kang Enbei, and Furuida [1]. - The competitive landscape shows that companies with registered capital exceeding 1.5 billion yuan are in the leading position, while those with capital between 500 million to 1.5 billion yuan are in the first tier, and companies with less than 500 million yuan are in the second tier [1]. Group 2: Regional Distribution - Representative enterprises in the hair medical industry are mainly distributed across provinces such as Shaanxi, Zhejiang, Jilin, Liaoning, Shandong, and Jiangsu, with a notable concentration in Shaanxi and Zhejiang [4]. Group 3: Market Dynamics - As of November 21, 2025, leading hair transplant chains like Yonghe Hair Transplant, Dama Micro-needle (Kefa Source), and Bilian Sheng have over 30 stores each [7]. - The market for Minoxidil, a common hair growth medication, is highly concentrated, with the top three brands holding over 97% market share in online pharmacies as of 2024 [10][14]. Group 4: Competitive Analysis - The hair transplant sector has many institutions with low concentration, leading to intense competition, while the market for Minoxidil is dominated by a few key players [12][16]. - The threat of new entrants is moderate due to certain industry barriers, while substitutes like wigs and hair tattoos pose a threat due to their lower cost and quicker application [16].

Core Viewpoint - *ST Meigu's 2025 performance forecast indicates expected revenue of approximately 850 to 1,050 million yuan, with a net loss attributable to shareholders projected between 550 to 390 million yuan. The company anticipates a significant increase in net assets by the end of the period due to the completion of its restructuring plan [1][1]. Group 1 - The company received a civil ruling from the Intermediate People's Court of Xiangyang on December 29, 2025, confirming the completion of its restructuring plan, which has effectively resolved its debt crisis and significantly improved its asset-liability structure [1][1]. - The restructuring involved introducing investors and adjusting equity, leading to a substantial increase in the company's net assets by the end of the reporting period [1][1]. Group 2 - The medical beauty business faces increasing competition and challenges in customer acquisition, resulting in a year-on-year decrease in revenue and profit, prompting the company to make impairment provisions for related assets [1][1]. - The biobased fiber business has not shown effective improvement, leading the company to also make impairment provisions for relevant production lines [1][1].

Company Overview - The company primarily operates in the bio-based fiber and medical beauty sectors [6] - It expects to achieve operating revenue of approximately 850 to 1,050 million yuan in 2025, with a net loss attributable to shareholders ranging from 550 to 390 million yuan [6] Financial Performance - The company has undergone a restructuring process, which has significantly improved its debt situation and asset-liability structure, leading to a substantial increase in net assets by the end of the reporting period [6] - The medical beauty business has faced intensified competition, resulting in a decrease in both revenue and profit, prompting the company to make impairment provisions for related assets [6] - The bio-based fiber business has not shown effective improvement, leading to additional impairment provisions for relevant production lines [6] Revenue and Profit Trends - Historical total revenue and net profit figures indicate fluctuations, with total revenue projected to decline in 2022 and 2023, followed by a recovery in 2024 and 2025 [7] - The year-on-year growth rates for total revenue and net profit have shown significant variability, with a notable decline of 36.92% in 2022 and a projected recovery of 19.77% in 2024 [7]

南财智讯1月29日电，*ST美谷发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为亏 损3.90亿元—5.50亿元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为亏损5.50 亿元—7.80亿元。公司预计2025年实现营业收入约8.5至10.5亿元，归属于上市公司股东的净利润亏损约 5.5至3.9亿元，预计期末净资产转正并大幅增长，主要原因如下：1、2025年12月29日，公司收到湖北省 襄阳市中级人民法院（以下简称"襄阳中院"）送达的（2025）鄂06破17号之一《民事裁定书》，鉴于相 关事项已达到《奥园美谷科技股份有限公司重整计划》（以下简称《重整计划》）第七部分第四条规定 的执行完毕标准，《重整计划》已经执行完毕，襄阳中院裁定终结公司重整程序。在重整程序中，公司 通过引入重整投资人、实施出资人权益调整等方式，有效化解了公司债务危机，极大地改善了公司资产 负债结构，大幅提高了公司期末净资产。2、报告期内，医疗美容业务市场竞争越趋激烈、客户开拓难 度加大，公司医疗美容业务营业收入和利润同比有所减少，公司对相关资产计提了减值准备；生物基纤 维业务经营未得到有效改善，公司对相关生 ...

证券代码：000615 证券简称：*ST美谷 公告编号：2026-021 奥园美谷科技股份有限公司 关于公司股票可能被终止上市的风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、奥园美谷科技股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日 在巨潮资讯网（www.cninfo.com.cn）披露了《关于公司股票实施退市风险警示和 其他风险警示暨停牌的公告》，公司股票于 2025 年 4 月 30 日开市起被实施退市 风险警示和其他风险警示。若公司 2025 年度出现《深圳证券交易所股票上市规 则（2025 年修订）》（以下简称《股票上市规则》）第 9.3.12 条规定的相关情 形，公司股票存在被终止上市的风险。 2、根据《股票上市规则》第 9.3.6 条"上市公司因触及本规则第 9.3.1 条第 一款第一项至第三项情形，其股票交易被实施退市风险警示后，应当在其股票交 易被实施退市风险警示当年会计年度结束后一个月内，披露股票可能被终止上市 的风险提示公告，在首次风险提示公告披露后至年度报告披露前，每十个交易日 披露一次 ...

*ST美谷公告称，公司股票于2025年4月30日起被实施退市及其他风险警示。若2025年度出现《股票上 市规则》规定情形，股票存在被终止上市风险。公司预计2025年营收8.5亿-10.5亿元，扣除后营收8.5 亿-10.5亿元；利润总额-5.7亿至-4亿元；归母净利润-5.5亿至-3.9亿元；扣非后净利润-7.8亿至-5.5亿元； 年末归母所有者权益15.4亿-20亿元。业绩预告未经审计，存在不确定性。本次为首次风险提示公告， 年报披露前每10个交易日披露一次。 ...

Core Insights - The medical beauty sector experienced a rise of 2.96% on January 29, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] Medical Beauty Sector Performance - Ai Meike (300896) closed at 144.38, with a gain of 4.53%, trading volume of 56,700 shares, and a transaction value of 803 million [1] - Huaxi Biological (688363) closed at 46.31, up 1.47%, with a trading volume of 45,900 shares and a transaction value of 211 million [1] - Jinbo Biological (920982) closed at 226.88, up 1.35%, with a trading volume of 8,287 shares and a transaction value of 1.86 billion [1] - ST Meigu (000615) closed at 3.13, down 1.26%, with a trading volume of 103,100 shares and a transaction value of 32.32 million [1] Capital Flow Analysis - The medical beauty sector saw a net inflow of 105 million from main funds, while retail investors experienced a net outflow of 33.44 million [1] - Ai Meike had a main fund net inflow of 103 million, representing 12.77%, with retail outflows of 38.71 million [2] - Huaxi Biological had a main fund net inflow of 10.25 million, representing 4.86%, with retail outflows of 1.15 million [2] - Jinbo Biological had a main fund net inflow of 9.45 million, representing 5.09%, with retail inflows of 1.25 million [2] - ST Meigu had a main fund net outflow of 7.90 million, representing -24.43%, with retail inflows of 4.02 million [2]